Phase 2 Trial of MLN9708 in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib

Trial Profile

Phase 2 Trial of MLN9708 in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Ixazomib (Primary) ; Cyclophosphamide; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Oct 2016 Interim results assessing efficacy and toxicity of two different doses of ixazomib 4 mg and 5.5mg given weekly with dexamethosone (n=70), published in the Blood Journal.
    • 04 Oct 2016 Interim results (n=70) published in the Blood.
    • 12 Sep 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top